Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
"On "23/10/2024", the "Medicines and Healthcare products Regulatory Agency (MHRA)" issued an update regarding "Donanemab licensed for early stages of Alzheimer’s disease in adult patients who have one or no copies of apolipoprotein E4 gene". This license is based on positive results from a Phase III study, where donanemab showed efficacy in slowing the progression of Alzheimer's disease. The drug has been approved to treat adults with mild cognitive impairment and dementia, and will be available under strict conditions to minimize risks."
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
